Dexcom Products

Proven Outcomes

DIaMonD study shows Dexcom CGM System* use results in significant benefits for MDI patients.

You are here

Dexcom CGM Use Lowers A1C by 1.0%<sup>1</sup>

Dexcom Continuous Glucose Monitoring (CGM) System users on a multiple daily injections (MDI) insulin regimen showed an average A1C reduction of 1% after 24 weeks of regular use, compared to baseline. Additionally, 52% of subjects in the study had a ≥1% A1C reduction.1

Significant A1C Reduction in Uncontrolled Patients

Participants with a baseline A1C of 8.5% showed an average 1.3% reduction.1

High Rate of Adherence

At week 24, 93% of study participants were still using the Dexcom CGM System ≥ 6 days/week.1

Increased Time Spent in Range

The Dexcom CGM System significantly increased time spent in range from baseline (70-80 mg/dL)—an additional 1.2 median hours (+72 minutes).1

Reduction of Hypoglycemia

CGM users showed a 79% reduction in hypoglycemia at night (11 median minutes).1

1Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017;317(4):371-378.

*Study conducted using the Dexcom G4® PLATINUM CGM System, which uses the same software as the Dexcom G5® Mobile CGM System.

Request Dexcom Information for Your Practice

If you are a clinician and want to learn more about Dexcom’s Continuous Glucose Monitoring Systems, please fill out the form and a Dexcom representative will contact you.

If you have diabetes and are interested in getting started with Dexcom CGM, please contact us here.

The information you provide will be sent securely and subject to the Dexcom Terms of Use and Privacy Policy.